---
layout: default
title: 1 2-Docosahexanoyl-Sn-Glycero-3-Phosphoserine Calc
parent: 僅模型預測 (L5)
nav_order: 13
evidence_level: L5
indication_count: 0
---

# 1 2-Docosahexanoyl-Sn-Glycero-3-Phosphoserine Calc
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Nutrient Complex (DHA-PS / EPA-PS / B-Vitamins / Minerals): From Unknown Indication to No Prediction Available

## One-Sentence Summary

This candidate is a 16-ingredient multi-nutrient combination comprising phospholipids (DHA-PS, EPA-PS, phosphatidylserine), B-vitamin cofactors (cobamamide, cocarboxylase, FAD, folic acid, leucovorin, levomefolate, pyridoxal phosphate, NADH), and mineral complexes (magnesium ascorbate, magnesium L-threonate, ferrous cysteine glycinate, zinc ascorbate, betaine).
The TxGNN pipeline returned **no predicted indications** for this candidate, most likely because the multi-ingredient query string could not be resolved to a single DrugBank node in the knowledge graph.
As a result, **no clinical evidence table can be generated**, and the evaluation must be classified as **Hold** pending data remediation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no regulatory authorization found) |
| Predicted New Indication | None (TxGNN returned no results) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no actual predictions returned |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate, so a mechanistic plausibility analysis cannot be performed at this time.

The combination consists entirely of endogenous cofactors and micronutrients. Several ingredients — phosphatidylserine, DHA-PS, EPA-PS, magnesium L-threonate, and NADH — have individual literature suggesting roles in neuronal membrane integrity, mitochondrial energy metabolism, and one-carbon cycle regulation. Betaine, folic acid, leucovorin, levomefolate, and pyridoxal phosphate collectively support methylation pathways. This profile is consistent with formulas targeting cognitive decline or neurodegenerative conditions, but this is a literature-level inference only, **not** a TxGNN-derived prediction.

The fundamental obstacle is identity resolution: the Evidence Pack contains 16 named ingredients in a single query string with no DrugBank ID assigned. The TxGNN knowledge graph operates on individual DrugBank nodes; a compound multi-ingredient string cannot be matched. Each ingredient would need to be evaluated independently or the combination would need a registered product identity before a meaningful repurposing prediction can be generated.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no predicted indications because the system could not resolve a 16-ingredient query string to any node in the drug–disease knowledge graph. Without a prediction score, a repurposing hypothesis, or regulatory authorization, there is no evaluable candidate at this stage.

**To proceed, the following is needed:**

- **Resolve drug identity**: Assign a DrugBank ID to the combination product, or decompose the query into individual ingredient-level TxGNN runs (one prediction per active ingredient), then aggregate results.
- **Establish original indication**: Determine the registered therapeutic indication or intended use category for this formulation (e.g., dietary supplement, pharmaceutical, OTC) in at least one jurisdiction.
- **Obtain safety data**: Download the package insert or regulatory dossier to fill DG001 (warnings/contraindications) and DG002 (MOA), both of which are currently blocking.
- **Re-run Evidence Pack pipeline**: Once a valid DrugBank node is identified, re-query TxGNN, ClinicalTrials.gov, and PubMed to populate the `predicted_indications` array.
- **Consider ingredient-level analysis**: If the combination has no single regulatory identity, a parallel multi-drug report (one per ingredient) may be the only viable path to generating actionable repurposing hypotheses.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

